Alembic Pharmaceuticals Gains USFDA Approval for Travoprost Solution

Alembic Pharmaceuticals Limited has announced the receipt of final approval from the US Food & Drug Administration for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004%. The approval was granted on 18th December 2025. This solution is an ionic buffered solution and is therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution, 0.004%, by Sandoz Inc.

The Travoprost Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The estimated market size for this product is USD 61 million for the twelve months ending September 2025, according to IQVIA data.

With this approval, Alembic Pharmaceuticals has a cumulative total of 232 ANDA approvals from the USFDA, which includes 212 final approvals and 20 tentative approvals. This development is part of Alembic’s ongoing efforts to expand its portfolio of generic pharmaceutical products in the United States.

Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It has been active in the healthcare sector since 1907. The company manufactures and markets generic pharmaceutical products globally. Alembic’s research and manufacturing facilities are approved by regulatory authorities in several developed countries, including the USFDA. The company is recognized as a leader in branded generics in India, with a field force of over 5500 representatives.